Trastuzumab biosimilar - Nanogen Biopharmaceutical
Latest Information Update: 21 Mar 2014
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Breast cancer; Gastric cancer
Most Recent Events
- 21 Mar 2014 Early research in Gastric cancer in Vietnam (IV)
- 21 Mar 2014 Early research in Breast cancer in Vietnam (IV)